We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
51
PUT
DELISTED
Exact Sciences
EXAS
$7.72M 0.32%
4,293
+802
+23% +$18.4K
PRGO icon
52
CALL
Perrigo
PRGO
$1.43B
$7.72M 0.32%
491
-434
-47% -$79.6K
KITE
53
DELISTED
Kite Pharma, Inc.
KITE
$7.63M 0.31%
137,099
+133,427
+3,634% +$8.39M
BLUE
54
CALL
DELISTED
bluebird bio
BLUE
$7.61M 0.31%
69
-41
-37% -$74.8K
ACAD icon
55
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$7.47M 0.31%
2,259
+1,829
+425% +$76.1K
VTRS icon
56
CALL
Viatris
VTRS
$20.8B
$7.03M 0.29%
1,747
-1,030
-37% -$57.4K
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$262M
$6.77M 0.28%
4,039
+3,249
+411% +$6.69M
MNKD icon
58
PUT
MannKind Corp
MNKD
$1.21B
$6.7M 0.28%
4,175
-114
-3% -$2.42K
BPMC
59
DELISTED
Blueprint Medicines
BPMC
$6.58M 0.27%
308,504
+6,700
+2% +$185K
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.56M 0.27%
71,757
+53,352
+290% +$5.93M
ALNY icon
61
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
$6.34M 0.26%
789
+394
+100% +$43.8K
APC
62
DELISTED
Anadarko Petroleum
APC
$6.18M 0.25%
102,300
+11,329
+12% +$805K
APC
63
PUT
DELISTED
Anadarko Petroleum
APC
$6.18M 0.25%
1,023
-500
-33% -$35.5K
NVAX icon
64
PUT
Novavax
NVAX
$1.21B
$5.95M 0.25%
421
+76
+22% +$17K
SRPT icon
65
PUT
Sarepta Therapeutics
SRPT
$1.63B
$5.89M 0.24%
1,836
+159
+9% +$5.39K
VXZ
66
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$5.86M 0.24%
112,625
+125
+0.1% +$5.79K
ONCE
67
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.85M 0.24%
1,402
+504
+56% +$26.3K
ONCE
68
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.75M 0.24%
1,379
+620
+82% +$32.4K
TXMD icon
69
CALL
TherapeuticsMD
TXMD
$23.8M
$5.74M 0.24%
196
+67
+52% +$23.8K
NBIX icon
70
CALL
Neurocrine Biosciences
NBIX
$18.4B
$5.58M 0.23%
1,403
+20
+1% +$967
PHG icon
71
CALL
Philips
PHG
$25B
$5.57M 0.23%
+3,317
New +$61.7K
ITCI
72
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.52M 0.23%
1,378
+237
+21% +$7.73K
OPK icon
73
PUT
Opko Health
OPK
$1.23B
$5.43M 0.22%
6,456
-1,040
-14% -$13.8K
HALO icon
74
CALL
Halozyme
HALO
$9.9B
$5.39M 0.22%
4,014
– –
EXAS
75
DELISTED
Exact Sciences
EXAS
$5.2M 0.21%
+289,112
New +$6.64M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.